Novel synthetic biomaterial is designed to support volumetric tissue regeneration while minimizing inflammatory foreign-body response SAN DIEGO, Sept. 23, 2026 /PRNewswire/ — Tempo Therapeutics, Inc. (“Tempo”), a clinical-stage regenerative medicine company pioneering synthetic…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
